Bristol-Myers Squibb Company

(

BMY

) pushed the Drugs industry higher today making it today's featured drugs winner. The industry as a whole closed the day down 0.2%. By the end of trading, Bristol-Myers Squibb Company rose 39 cents (1.3%) to $31.50 on light volume. Throughout the day, 9.7 million shares of Bristol-Myers Squibb Company exchanged hands as compared to its average daily volume of 13.7 million shares. The stock ranged in a price between $31.16-$31.65 after having opened the day at $31.17 as compared to the previous trading day's close of $31.11. Other companies within the Drugs industry that increased today were:

Marina Biotech Inc

(

MRNA

), up 22.9%,

Inhibitex Inc

(

INHX

), up 20.2%,

YM Biosciences Inc

(

YMI

), up 19.8%, and

Salix Pharmaceuticals

(

SLXP

), up 12.6%.

Bristol-Myers Squibb Company, a global biopharmaceutical company, discovers, develops, and delivers innovative medicines that help patients prevail over serious diseases. Bristol-Myers Squibb Company has a market cap of $51.11 billion and is part of the

health care

sector. The company has a P/E ratio of 15.5, equal to the average drugs industry P/E ratio and below the S&P 500 P/E ratio of 17.7. Shares are up 17.5% year to date as of the close of trading on Monday.

TheStreet Ratings rates Bristol-Myers Squibb as a

buy

. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, reasonable valuation levels, solid stock price performance and good cash flow from operations. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity.

On the negative front,

DARA Biosciences Inc

(

DARA

), down 23%,

Accelr8 Technology Corporation

(

AXK

), down 15.1%,

Marshall Edwards Inc

(

MSHL

), down 13.9%, and

K-V Pharmaceutical Company

(

KV.B

), down 10.4%, were all losers within the drugs industry with

Gilead Sciences Inc

(

GILD

) being today's drugs industry loser.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider

SPDR S&P Pharmaceuticals ETF

(

XPH

) while those bearish on the drugs industry could consider

ProShares UltraShort Nasdaq Biotech

(

BIS

).

null